Early research (Phase 1)Ended earlyNCT05318963
What this trial is testing
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Institute of Hematology & Blood Diseases Hospital, China 14